Biodesix (NASDAQ:BDSX) Issues Earnings Results

Biodesix (NASDAQ:BDSX) released its earnings results on Thursday. The company reported ($0.75) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.75), FiscalAI reports. Biodesix had a negative net margin of 26.97% and a negative return on equity of 788.19%. The firm had revenue of $24.04 million for the quarter, compared to analysts’ expectations of $27.49 million.

Here are the key takeaways from Biodesix’s conference call:

• Biodesix reported Q3 revenue of $24.0 million, up 10%, and diagnostic test volume up 24%, but results fell short of expectations. Management attributed the shortfall to fewer sales representatives than planned, weaker-than-expected primary-care seasonality and delayed development-services projects.
• The company lowered its 2026 revenue outlook to $101 million–$103 million, or about 15% growth at the midpoint. Management expects development-services revenue to remain near $1 million in Q4, with many projects shifting into 2027; it also said a higher mix of Nodify CDT tests is weighing on average revenue per test.
• Commercial capacity has improved to about 110 representatives, with a target of 115 by year-end. Management said October was its strongest month of new-physician acquisition this year and expects added sales capacity and improved forecasting to support a recovery, while noting new hires take time to ramp.
• Biodesix cited the CHEST lung-nodule management framework and early enterprise-wide integrations at two major health systems as support for broader use of its Nodify tests. These system-level rollouts could make adoption more scalable, though management cautioned that implementation takes time.
• The company is expanding beyond blood-based diagnostics with a radiomic lung-nodule test targeted for commercialization in 2028 and two MRD assay programs developed with Bio-Rad and Thermo Fisher. These initiatives broaden its longer-term opportunity, but remain in development.

Biodesix Stock Performance

NASDAQ:BDSX traded down $1.65 on Thursday, reaching $19.84. 185,258 shares of the company’s stock were exchanged, compared to its average volume of 78,704. The company has a debt-to-equity ratio of 5.12, a current ratio of 2.85 and a quick ratio of 2.85. The firm has a market cap of $209.33 million, a price-to-earnings ratio of -6.26 and a beta of 0.65. Biodesix has a 52 week low of $5.26 and a 52 week high of $31.97. The stock has a fifty day simple moving average of $25.93 and a 200-day simple moving average of $18.90.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BDSX. Canaccord Genuity Group lifted their price target on shares of Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Weiss Ratings raised Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, September 8th. HC Wainwright reissued a “buy” rating on shares of Biodesix in a report on Thursday, October 22nd. Finally, TD Cowen reissued a “buy” rating and issued a $40.00 target price (up from $30.00) on shares of Biodesix in a research report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Biodesix has a consensus rating of “Moderate Buy” and a consensus price target of $36.25.

Insider Buying and Selling at Biodesix

In other Biodesix news, Director Jack Schuler purchased 15,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were bought at an average price of $24.47 per share, with a total value of $367,050.00. Following the completion of the transaction, the director directly owned 555,810 shares in the company, valued at approximately $13,600,670.70. This trade represents a 2.77% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders have bought a total of 42,600 shares of company stock valued at $1,033,062 in the last three months. 23.20% of the stock is owned by company insiders.

About Biodesix

Biodesix, Inc is a data-driven diagnostic solutions company focused on improving the diagnosis and treatment of lung diseases, including lung cancer. The company combines proprietary molecular diagnostic technologies, clinical data, and artificial intelligence to help physicians assess disease risk and make more informed treatment decisions.

Its offerings include blood-based tests designed to help evaluate indeterminate pulmonary nodules, identify patients who may be at higher risk of lung cancer, and support treatment selection and monitoring.